← Full evidence page

For the cleanest result, disable browser headers and footers.

Dediabetes Evidence Brief

Diabetes Treatment Safety: Adverse Events and Side Effect Evidence

Evidence related to adverse events, serious safety outcomes, gastrointestinal events, urinary tract infections, DKA, hyperglycemia, and treatment tolerability in diabetes studies.

Brief accessed
—

Full evidence pagehttps://www.dediabetes.com/evidence/adverse-events-safety

Executive Summary

Adverse Events and Safety evidence appears to center on Semaglutide.

Among 18 indexed studies and 7 interventions, the strongest signals are summarized from the available evidence. Semaglutide appears to be one of the clearer current evidence signals.

  • Evidence is consistently positive across multiple studies.
  • Some evidence is positive, but results are not consistent across all studies.
  • Early findings are encouraging, but stronger trials are needed.

Caution

This summary reflects the currently indexed evidence and should not be interpreted as treatment advice.

Evidence Snapshot

Studies analyzed
18
Evidence relationships
14
Interventions
7
Outcomes
5
Strong evidence signals
2
Mixed evidence areas
0

Key Findings

  1. 01

    Across 3 studies, Metformin shows a evidence signal for Total daily insulin dose.

  2. 02

    Across 4 studies, Semaglutide shows a consistent evidence signal for Adverse events incidence.

  3. 03

    Across 2 studies, Insulin therapy shows a consistent moderate positive signal for Total daily insulin dose.

  4. 04

    Across 1 study, Dapagliflozin shows a neutral signal for Adverse events incidence.

Question Highlights

Does Semaglutide reduce adverse events incidence?

Semaglutide may improve Adverse events incidence.

Strong evidence is based on 4 supporting studies.

Population details are unavailable.

Read the full answer

Does Metformin improve total daily insulin dose?

Metformin may improve Total daily insulin dose.

Strong evidence is based on 3 supporting studies.

Population details are unavailable.

Read the full answer

Does Insulin therapy improve total daily insulin dose?

Insulin therapy may improve Total daily insulin dose.

Moderate evidence is based on 2 supporting studies.

Only a small number of supporting studies are available.

Read the full answer

Evidence Categories

The evidence is organized by how consistently it supports a conclusion and how much research is available.

Well-Supported Interventions

The strongest and most consistent evidence for improving this outcome.

Evidence is consistently positive across multiple studies.

Why it matters

Consistent positive findings are easier to interpret than isolated or mixed results.

Interpretation

Semaglutide appears to have a consistent beneficial signal in the indexed evidence.

Leading examples

Semaglutide · Metformin · Insulin therapy

Evidence basis: 9 evidence pairs - 13 studies

Findings Requiring Careful Interpretation

Results that vary across studies or depend on population, study design, duration, or comparator.

Some evidence is positive, but results are not consistent across all studies.

Why it matters

Mixed results suggest effects may depend on population, comparator, duration, or study design.

Interpretation

Semaglutide is mixed in the currently indexed evidence.

Caution

Some supporting studies reported neutral, negative, or mixed findings.

Leading examples

Semaglutide · Metformin · Insulin therapy

Evidence basis: 11 evidence pairs - 15 studies

Emerging Areas of Research

Early positive signals that require additional high-quality research.

Early findings are encouraging, but stronger trials are needed.

Why it matters

Promising signals can guide further review, but they should not be treated as settled evidence.

Interpretation

Metformin may have a beneficial signal, but the evidence base is still developing.

Caution

Current support is limited by study volume, RCT depth, or evidence strength.

Leading examples

Metformin · Insulin therapy

Evidence basis: 5 evidence pairs - 6 studies

About this Evidence Brief

This brief summarizes research currently indexed by Dediabetes Evidence Intelligence. It is not a clinical guideline or personalized medical recommendation. Evidence classifications may change as additional studies are indexed.

Suggested citation

—